Eventide Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Eventide Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-90,000	Closed	-$2M	–	136
2017 Q1	$2M	Hold	90,000	–	–	0.13%	93
2016 Q4	$1.7M	Hold	90,000	–	–	0.11%	97
2016 Q3	$2.7M	Hold	90,000	–	–	0.16%	90
2016 Q2	$3.46M	Hold	90,000	–	–	0.21%	79
2016 Q1	$3.43M	Hold	90,000	–	–	0.19%	85
2015 Q4	$3.96M	Buy	+90,000	New	+$4.46M	0.2%	95

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eventide Asset Management's JUNO Position: Q2 2017 in Review

Eventide Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 90,000 shares — an estimated $2M sold.

Eventide Asset Management first reported a position in JUNO in Q4 2015 and held it in 6 quarters. The position peaked at $3.96M in Q4 2015. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

Eventide Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Eventide Asset Management sold 90,000 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $2M.
Eventide Asset Management first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
Eventide Asset Management's Juno Therapeutics, Inc. position peaked at $3.96M in Q4 2015.
173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.